Source

Molecular Characterization

Recombinant mIL-17A contains no "tags" and the nonglycosylated protein has a calculated MW of 15,377. DTT-reduced protein migrates as a 15-22 kDa polypeptide. Heterogeneity in SDS PAGE is due to glycosylation. The non-reduced cystine-linked homodimer migrates as a 28-36 kDa protein. The expected amino-terminal TVKAA of recombinant mIL-17A was verified by amino acid sequencing.

Purity

>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mIL-17A. All lots are greater than 98% pure.

Bioactivity

The bioactivity of recombinant mIL-17A was determined by its ability to induce mouse IL-6 production by 3T3 MEFs WT. The ED50 of each lot is between 0.4-1.4 ng/ml.

Coomassie Gel

The purity of recombinant mIL-17A was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant mIL-17A and staining overnight with Coomassie Blue.

Bioactivity

The production of mouse IL-6 by 3T3 MEFs WT cultured with increasing concentrations of mIL-17A was assessed. Media from cells incubated with mIL-17A for 24 hours was collected and assayed for mouse IL-6 by ELISA and the OD450-OD650 was determined.

Formulation

Background

IL-17A is a cystine-linked homodimeric pro-inflammatory cytokine produced by Th17 cells, a distinct CD4+ T cell lineage (1,2). IL-17A stimulates the production of the pro-inflammatory cytokines IL-1β, TNFα, and IL-6. IL-17A also induces production of the neutrophil chemoattractants IL-8, CXCL1, and CXCL6 thereby bridging adaptive and innate immunity (1,2). IL-17A is intimately involved in mucosal immunity against bacterial infections (1,3) and has a putative role in some autoimmune disorders (1,4). IL-17A effects appear to be exerted primarily through binding to the IL-17RA (5). IL-17A binding induces production of cytokines, chemokines and other proteins through activation of the Erk1/2 MAP kinase, PI3K/Akt, p38, and NF-κB pathways (3,4,6). Phosphorylation of some Jaks and Stats has been observed.